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Abstract:
The purpose of this study is to use photoactive vitamin nanoparticles as photodynamic
antimicrobial chemotherapeutic agent to treat patients with chronic wounds. Chronic wounds are
considered as a pandemic health problem which affects millions of people and increases ~10 %
annually. According to the American Academy of Dermatology, the expense of treating chronic
wounds constitutes over half of the total cost for all skin diseases. The main cause of chronic
wounds is due to the existence of biofilms. Biofilms are complex microbial communities
containing and are reported to be major factor contributing to multiple chronic inflammatory
diseases. Owing to bacterial species with in biofilms being exceptionally resisted to many
traditional therapies, Photodynamic Antimicrobial Chemotherapy (PACT) can provide an
effective alternative antimicrobial, antifungal, and antiviral treatment for drug-resistant
microorganism. PDT uses both light and nontoxic vitamin photosensitizers to destroy specific
targeted cells. The main advantage of PACT would be that it is very unlikely for bacteria to
develop resistance to reactive oxygen species. However, the main limitation of this technique
would be the uptake kinetics of the photo sensitizers in microorganisms. We have developed a
unique nano-emulsion to increase the solubility of these otherwise hard to dissolve, hydrophobic
vitamins for faster, more effective delivery to the targeted cells. This provides a photodynamic
chemotherapeutic regime for the treatment of chronic wound ulcers caused by microbial
biofilms.
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Introduction:
Chronic wounds are the major public health problem affecting millions of individuals. The term
“chronic wound” is generally accepted, but yet no simple definition has been agreed upon.1 A
mechanistic definition such as “those not following normal wound healing trajectory” have
proposed but the most common definition have been “ulcers (wounds) older than 3 months of
age”. No matter the length of time, a wound which does not heal in an orderly progression but
halts in an inflammatory process is considered a chronic wound. 1-2 The treatment of chronic
wounds is often inadequate, extremely painful, time consuming, and costly. Approximately $25
billion is spent annually on the treatment of chronic wounds.
Chronic wounds, includes diabetic food ulcers, pressure ulcers, and venous leg ulcers. The
elderly are affected the most by these ulcers which penetrate deep into the skin and become
infected easily.3 It has been estimated that 15% of individuals with diabetes mellitus will develop
lower extremity ulcers and 14-24% of diabetic patients with foot ulcers will eventually undergo
amputation. Approximately 100,000 lower limb amputations are performed in diabetic patients
each year in the United State. 4-6 Pressure ulcers are common and expensive problem in acute
care, rehabilitation unit, nursing home, and home care populations. Venous leg ulcers are often
painful inflictions that have been estimated to affect 1% of the world’s population. The statistical
data shows a great need for the treatment of chronic wounds.

6-7

There are biological and

physiological reasons for wounds that are not healing. A primary barrier to healing is the
continuing influx of poly-morphonuclear leukocytes (PMNs, a category of white blood cells)
from the host blood circulatory system to the open wounds. Activated PMNs release cytotoxic
enzymes and inflammatory mediators that can damage host tissues. 8-10 Owing to this continuous
influx of PMNs, the healing and the destructive processes within the chronic wounds are
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imbalanced; and the main reason for this distress is the presence of biofilms. Biofilm-related
diseases are typically persistent infections that develop slowly, seem to be rarely resolved by
immune defenses, and respond transiently to antimicrobial therapy.
Biofilm are defined as a group of microorganisms that exist in a self-synthesized protective
matrix and are encased within a three dimensional matrix of extracellular polymeric substances.
Extracellular polymeric substance provides physical protection to the microorganisms from the
environment. They are extremely difficult to detect in chronic wounds and exceptionally
resistant to the host immune system as well as antibiotic elimination. Currently, the management
of infections due to biofilms is physical removal by a method called surgical debridement.11 The
procedure requires aggressive abstraction of necrotic tissue until healthy tissue is visible.
Hypothetically, this is the preferred method, but due to its aggressive nature it’s not always the
optimum choice. Risks can be life threatening to patients such as anesthesia, bleeding, sepsis,
and bacteremia. 11,12
The use of non-invasive Photodynamic Antimicrobial Chemotherapy (PACT) can overcome
problems which are associated with the current treatment of chronic wounds. The principle of
PACT is the same as that of traditional photodynamic therapy. It is a non-intrusive technique that
uses a combination of light and nontoxic drugs (photosensitizers) to destroy targeted cells. Once
the inactive, nontoxic drug is put on either topically or injected it can only be activated by
irradiation at a certain wavelength After the drug is irradiated it can then produce extremely
reactive oxygen species to destroy those cells which were targeted without causing damage to
any healthy tissue. Once the irradiation is removed, the photosensitive drug will return to its
stable, non-harmful state. The main limitation of PACT is the uptake kinetics of the nontoxic
drug in microorganisms. Generally, neutral, anionic, and cationic photosensitizers can effectively

Page 4 of 17

eradicate Gram-positive bacteria.13 The only photosensitizer that can kill Gram-negative bacteria
is hydrophilic cationic. Gram-positive bacteria have a porous cell wall which lets most
photosensitizers to cross. On the other hand, the cell envelop, outer membrane, of Gram-negative
bacteria forms an effective permeability obstruction between the cell and environment.14
Therefore, intensive research has been done on particulate delivery systems to overcome this
situation. Nanoemulsion studies have been found to be an efficient carrier for biomedical
applications that improves efficacy in solubilizing, protecting, and targeting drugs for specified
delivery.15-17

Hence this approach can be used to improve current chronic wound diagnostics

and treatments.

Experiment:
Preparation of Nanoemulsion Formulations:

The nanoemulsion drug is being prepared for optimal drug delivery. We have chosen
hydrophobic photosensitizers which are less permeable to cross the cell barrier. Many studies
have shown that using nanoemulsions as carriers for biomedical applications can improve
efficacy in solubilizing, protecting, and targeting microorganisms for specified delivery.
Therefore one can anticipate that our approach can greatly advance current chronic wound
treatment.
In this study we have chosen copper Phthalocyanine (CuPc) and riboflavin (vitamin B2)
as hydrophobic photosensitizers. The main reason for using this as a PACT agent is owing to the
certainty of its non-toxic nature towards human tissue. In order to promote the drug delivery oilin-water nanoemulsion formulations have been developed.
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Preparation of oil in water (o/w) nanoemulsion:
Formulation 1:
In this formulation we use Copper phthalocyanine (CuPc) which will have a final oil phase.
•

Dissolve 5.0 mg of copper phthalocyanine (CuPc) and 2.0 mL of surfynol-465
(surfactant, wetting agent) in 20 mL of ethyl acetate (organic phase) over low heat with
constant stirring.

•

2 gm of poly ethylene glycol (PEG200) is dissolved in 20 mL of water (water phase).

•

Add the organic phase into water phase drop by drop with vigorously stirring over low
flame until all the ethyl acetate has evaporated.

•

Sonicate for 20 minutes.

Preparation of water in oil in water (w/o/w) nanoemulsion:
•

A water-oil-water (w/o/w) double emulsion method is developed to entrap hydrophilic
vitamin riboflavin inside the double coated nanoparticles.

Formulation 2:
•

In this formulation we use riboflavin (vitamin B2), as photosensitizer.

•

First 30 mg of riboflavin and 2.0g poly ethylene glycol (PEG 200) is dissolved in 20 mL
of water (water phase).

•

Dissolve 20 mL of castor oil and 2.0mL of surfynol-465 (organic phase) over low heat
with constant stirring.
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•

The water phase is added drop by drop into the organic phase with constant stirring,
reverse micelles are formed in this step (w/o emulsion).

•

The final water phase is prepared by dissolving 2.0mL of polysorbate80 (surfactant) in 20
mL of water.

•

Finally, the w/o emulsion from above is added drop by drop into the final water phase
with constant stirring.

•

Keep stirring until all the water is evaporated, a double emulsion is formed in this step.

•

Surfynol-PEG is good pair of hydrophobic-hydrophilic double emulsion.

Formulation 3:
•

In this formulation we use riboflavin (vitamin B2), nanoparticles.

•

First 30 mg of riboflavin and 2.0g poly ethylene glycol (PEG 200) is dissolved in 20 mL
of water (water phase).

•

Dissolve 20 mL of castor oil and 2.0mL of surfynol-465 (organic phase) over low heat
with constant stirring.

•

The water phase is added drop by drop into the organic phase with constant stirring,
reverse micelles are formed in this step (w/o emulsion).

•

The final water phase is prepared by dissolving 2.0mL of poloxamer-407 in 20 mL of
water.

•

Finally, the w/o emulsion from above is added drop by drop into the final water phase
with constant stirring.

•

Keep stirring until all the water is evaporated, a double emulsion is formed in this step.
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•

Surfynol-PEG and Surfynol-Poloxamer-407 are all good pairs for a hydrophobichydrophilic double emulsion.

Bacteria Study and Cell count:
Each emulsion formulation will be tested for its ability to deliver the PACT drugs into bacteria
biofilm of E coli.
The biofilm of E coli (Gram negative) are successfully grown using CDC Bio-Reactor. Bioreactor is a one liter vessel with an effluent spout at approximately 400 ml. Continuous mixing of
the reactor’s bulk fluid is provided by a baffled stir bar that is magnetically driven. An UHMW
polyethylene top supports eight independent rods. Each rod houses three removable coupons
(biofilm growth surfaces) for a total of 24 sampling opportunities. The bioreactor operates as a
continuous flow stirred tank reactor, as such nutrients are continuously pumped into and flow out
of the reactor, leaving only biofilm.
The grown biofilm coupons are removed and drop each emulsion formulations on the top of the
coupons. Half of the coupons remain in the dark and the other half are incubated for 30 minutes
at 35˚C and then irradiated to light for 30 minutes.
Then the both the coupons that remains in dark and irradiate to light are removed and diluted 9x
times individually in tryptic soy broth, each in single test tube.
We have set four test tubes, each with 9 mL of sterile tryptic soy broth, and label from 1to4.
Then 1 mL sample is taken from the bacterial suspension that we wish to count and add it to the
first tube. Mix well, this is 1:10 dilution ratio because we have added 1 mL to 10mL total.
Then 1mLof dilution broth suspension is removed from tube 1 and added to tube 2. Mix well,
this dilution and each following mix increasingly will be diluted by a factor of 10. Thus, tube 2 is
1:100 dilutions.
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Then 1mLof dilution broth suspension is removed from tube 2 and added to tube 3. Mix well.
The same dilutions are followed for all the 4 tubes.
Then 1mLof dilution broth suspension is taken from tube 4 and added it to the surface of sterile
nutrient medium in a Petri dish. Spread evenly and incubate the plates upsides down allow the
bacteria to multiply for 24 to 48 hours at 37˚C.

Results:
The Petri plate after incubating to 24 to 48 hours, the bacterial colonies that grew on the plates
are counted.

Formulation 1:
We have seen that for formulation 1(copper phalocyanin) the bacterial cell count for the Petri
plates that remains on dark is 92 cells and for the Petri plates that irradiate to light are 0 cells.
Thus the percentage of bacteria that is killed is calculated as follows:
Number of colonies on the plate times the reciprocal of dilution factor gives the percentage of
killing the microorganisms.
Thus the % kill microorganisms is 100%

Formulation 2:
We have seen that for formulation 2 (Riboflavin with polysorbate80 as surfactant) the bacterial
cell count for the Petri plates that remains on dark is 147 cells and for the Petri plates that
irradiate to light are 0 cells. Thus the percentage of bacteria that is killed is calculated as follows:
Number of colonies on the plate times the reciprocal of dilution factor gives the percentage of
killing the microorganisms.
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Thus the % kill microorganisms is 100%

Formulation 3:
We have seen that for formulation 3 (riboflavin with poloxamer-407 as surfactant) the bacterial
cell count for the Petri plates that remains on dark is 897 cells and for the Petri plates that
irradiate to light are 142cells. Thus the percentage of bacteria that is killed is calculated as
follows:
Number of colonies on the plate times the reciprocal of dilution factor gives the percentage of
killing the microorganisms.
Thus the % kill microorganisms is 84.2%
Figure1

The above figures are the Petri plates which are after incubation to 35˚C.
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Figure 2

The above figure is the biofilm of E coli which are identified by scanning through electron
microscopy.

Bacteria Study:

The bacterial study of Copper Pthalocyanin and Riboflavin was conducted using biofilm of E.
coli. Each formulation will be tested for its ability to deliver the PACT drugs into bacteria. E coli
(Gram negative) are cultured in Petri dishes with nutrient broth culture media. A concentration
5.0 mg of copper pthalocyanin can kill 100% of bacteria after incubation followed by 0.5 h of
irradiation with low intensity light, ~5.0 J/cm2 and a concentration of 30 mg Riboflavin with
polysorbate 80 as a surfactant can kill 100% of bacteria, where as the concentration of 30mg
Riboflavin with poloxamer-407 as a surfactant can kill only 84.2% this is due to the less
penetration of the drug with poloxamer-407 as a surfactant. Our result indicates our
nanoemulsion can easily pass through the bacterial membrane and release the photosensitizes
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Formulation 1

Formulation 2

Formulation3

(copper pthalocyanin)

(Riboflavin with
polysorbate80)

(Riboflavin with
poloxamer-407)

Concentration

0.001

0.03

0.03

Dark

92 cells

147 cells

142 cells

Light

0 cells

0 cells

897 cells

% Kills

100%

100%

84.2%

Conclusion:
We have shown that photodynamic antimicrobial chemotherapy (PACT) has the potential to
represent an alternative antibacterial, antifungal, and antiviral treatment for drug-resistant
organisms. PDT uses both visible light (>395nm in wavelength) and a non-toxic vitamin
photosensitizer to destroy specific targeted cells. Nanoemulsion also has proven to be an
effective way for drug delivery. We have developed a unique nanoemulsion to increase the
solubility of these otherwise hard to dissolve, hydrophobic vitamins for the faster, more effective
delivery to the targeted cells. Thus the technique provides a photodynamic chemotherapeutic
regime for the treatment of chronic wound ulcers by microbial biofilm.
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